KRAS biomarker testing disparities in colorectal cancer patients in New Mexico.

about

KRAS biomarker testing disparities in colorectal cancer patients in New Mexico.

Item

http://www.wikidata.org/entity/Q47137265

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

KRAS biomarker testing disparities in colorectal cancer patients in New Mexico.

@en

KRAS biomarker testing disparities in colorectal cancer patients in New Mexico.

@nl

type

Item

label

KRAS biomarker testing disparities in colorectal cancer patients in New Mexico.

@en

KRAS biomarker testing disparities in colorectal cancer patients in New Mexico.

@nl

prefLabel

KRAS biomarker testing disparities in colorectal cancer patients in New Mexico.

@en

KRAS biomarker testing disparities in colorectal cancer patients in New Mexico.

@nl

P1476

KRAS biomarker testing disparities in colorectal cancer patients in New Mexico.

@en

P2093

Alissa Greenbaum

http://www.w3.org/2001/XMLSchema#string

Angela Lw Meisner

http://www.w3.org/2001/XMLSchema#string

Anita Y Kinney

http://www.w3.org/2001/XMLSchema#string

Ashwani Rajput

http://www.w3.org/2001/XMLSchema#string

Charles Wiggins

http://www.w3.org/2001/XMLSchema#string

Manuel Rojo

http://www.w3.org/2001/XMLSchema#string

P2860

Management of locally advanced and metastatic colon cancer in elderly patients

Does patient rurality predict quality colon cancer care?: A population-based study

Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.

Cancer statistics, 2016

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer

KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.

How does older age influence oncologists' cancer management?

P304

e00448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.HELIYON.2017.E00448

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29202108

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5701808

http://www.w3.org/2001/XMLSchema#string